secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0000950170-25-023742
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth
-------------------------------------------------------------------

- Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
- GAAP net loss $34M ($0.60 loss per share); adjusted EPS $0.44 vs $0.48.
- Orders outpaced sales by 6% in Q4; sequential revenue up 8%.
- FY2025 guidance: revenue $685-710M (8-12% reported growth, 10-14% ex-COVID).
- Closed acquisition of Tantti Laboratory; launched AVIPure dsRNA resin for mRNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/0000950170-25-023742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/rgen-20250220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-023742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer